雾化吸入布地奈德与可必特对慢性阻塞性肺疾病急性加重期患者的疗效被引量：11

Effects of Budesonide Suspension Combined with Combivent Inhaled on Patients with Acute Exacerbation of COPD

导出

摘要目的探讨布地奈德与可必特联合雾化吸入治疗慢性阻塞性肺疾病急性加重期(AEC0PD)的疗效。方法选择AECOPD患者54例,分为3组,每组18例。布地奈德组(A组)给予布地奈德混悬液2ml,喷射雾化吸入,每12h一次;联合组(B组)给予布地奈德混悬液2ml,可必特2.5ml喷射雾化吸入,每12h一次;对照组(C组)不使用任何吸入剂。观察期为7d。结果治疗后3组患者动脉血氧分压(PaO2)、动脉二氧化碳分压(PaCO2)、pH值、第一秒钟用力呼气容积、用力肺活量、深吸气量间差异均有统计学意义(P<0.05);治疗后A组、B组各项观察指标与C组比较,差异均有统计学意义(P<0.05)。结论联合雾化吸入布地奈德与可必特能更好地改善AE-COPD患者的气流受限,疗效优于单纯吸入布地奈德。 Objective To discussion the efficacy of nebulized budesonide suspension and budesonide suspension combined with Combivent in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease （ AECOPD ）. Methods Fifty - four patients with AECOPD were divided into three groups, with 18 in each group. The patients in group A received budesonlde nebulized suspension, 2mg every 12h; those in group B underwent budesonide suspension 2ml plus combined Combivent 2. 5ml by nebulization every 12h; those in group C as the control were not given any bronchodilator drugs and corticosteroids. Observation period was seven days. Results After treatment among the three groups there ware significant differences in arterial oxygenation （ PaO2 ） , arterial partial pressure of carbon dioxide （ PaCO2 ） , pH value, first - second forced expiratory volume （ FEV1 ） , forced vital capacity （ FVC ） and inspiratory capacity （ IC ）（ P 〈 0. 05 ） ; compared with the control group, the above parameters in both group A and B were significantly different （ P 〈 0. 05 ）. Conclusion Nebulized budesonide suspension combined with Combivent can improve airflow in AECOPD patients, which is better than budesonide nebulized suspension alone.

作者黄秀英叶熊程英平肖辉包红

机构地区上海市南汇区中心医院急诊科上海市南汇区中心医院呼吸科

出处《中国全科医学》 CAS CSCD 2008年第21期1977-1978,1980,共3页 Chinese General Practice

关键词肺疾病慢性阻塞性布地奈德混悬液可必特 Pulmonary disease, chronic obstructive Budesonide suspension Combivent

分类号 R563 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献7

1Celli BR, MacNcr W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD, a summary of the ATS/ERS position paper [ J ]. Eur Respir, 2004, 23 (6) : 932 - 946.
2Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [ Z]. Available from: www. goldcopd, com. 2006.
3吴海蓉,乔小民,李春.支气管肺泡灌洗治疗慢性阻塞性肺疾病合并呼吸衰竭疗效观察[J].疑难病杂志,2007,6(10):621-622. 被引量：4
4Maltais F, OstineUi J, Bourbeau J, et al. Comparison of Nebuhzed Budesonide and Oral Prednisolone with Placebo in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease [J].Am J Respir Crit Care Med, 2002, 165 (5): 698-703.
5Mirici A, Meral M, Akgun M. Comparison of the efficacy of nebulised budesonide with parenteral corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease [ J ]. Clin Drug Invest, 2003, 23 (1): 55-62.
6韩伟,周新.布地奈德雾化治疗在COPD急性加重期的应用[J].实用临床医药杂志,2004,8(2):6-8. 被引量：62
7Toru Oga MD, Koichi Nishimura MD, Mitsuhiro Tsukino MD, et al. A comparison of the effects of salbutamot and Ipratropium bromide on exercise endurance in patients with COPD [J]. Chest, 2003, 123 (6): 1810 - 1816.

二级参考文献15

1Pauwels R A,Buist A S,Calverley P M,et al.Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease.NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary[J].Am J Respir Crit Care Med,2001,163(5):1256.
2Renkema T E,Schouten J P,Koeter G H,et al.Effects of long-term treatment with corticosteroids in COPD[J].Chest,1996,109(5):1156.
3Maltais F,Ostinelli J,Bourbeau J,et al.Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease:a randomized controlled trial[J].Am J Respir Crit Care Med,2002,165(5):698.
4Oudijk E J,Lammers J W,Koenderman L.Systemic inflammation in chronic obstructive pulmonary disease[J].Eur Respir J,2003,46(11):5.
5Niewoehner D E,Erbland M L,Deupree R H,et al.Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease[J].N Engl J Med,1999,340(25):1941.
6Davies L,Angus R M,Calverley P M A.Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease:a prospective randomized controlled trial[J].Lancet,1999,354(9177):456.
7Osman L M,Godden D J,Friend J A R,et al.Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease[J].Thorax,1999,52(1):67.
8Decramer M,Gosselink R,Troosters T,et al.Muscle weakness is related to utilization of health care resources in COPD patients[J].Eur Respir J,1997,10(2):417.
9McEvoy C E,Ensrud K E,Bender E,et al.Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,1998,157(3):704.
10Johnell O,Pauwels R,Lofdahl C G,et al.Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler[J].Eur Respir J,2002,19(6):1058.